Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Wall Street Review: Stock Rally Broadens as S&P 500, Nasdaq Hit New Record Highs
By Panos Mourdoukoutas Wall Street’s multi-week rally turned into an “everything rally” this week amid lower oil prices, steady bond...
FIFA Triples Price to $32,970 for Its Best Available Tickets to the World Cup Final
By The Associated Press FIFA tripled the price of its best available tickets to the World Cup final, making $32,970...
Fallout Nuka Girl: Release Date, Pricing and More
Have you ever explored the world of the Fallout video gaming series? If yes, you must have probably seen the...
US to Host New Israel–Lebanon Peace Talks
By Ryan Morgan The United States will again host a set of talks between Israeli and Lebanese delegations on May...
US Fighter Jet Disables 2 Iranian Tankers in Blockade Enforcement Action: CENTCOM
By Ryan Morgan A U.S. fighter jet fired on a pair of crude oil tankers as they attempted to bypass...
OpenAI Cofounder Greg Brockman Defends Company’s For-Profit Pivot—and His Own $30 Billion Payday
By Beige Luciano-Adams In the second week of a high-profile jury trial that could have a profound impact on the...